Black Swift Group LLC Sells 37,720 Shares of Novo Nordisk A/S (NYSE:NVO)

Black Swift Group LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 72.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,280 shares of the company's stock after selling 37,720 shares during the quarter. Black Swift Group LLC's holdings in Novo Nordisk A/S were worth $1,700,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its holdings in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company's stock valued at $34,463,000 after buying an additional 37,346 shares in the last quarter. Private Wealth Partners LLC lifted its position in Novo Nordisk A/S by 155.1% during the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company's stock worth $3,953,000 after buying an additional 20,188 shares in the last quarter. Channel Wealth LLC grew its holdings in shares of Novo Nordisk A/S by 15.6% in the third quarter. Channel Wealth LLC now owns 57,353 shares of the company's stock valued at $6,829,000 after purchasing an additional 7,756 shares during the period. Buckingham Capital Management Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $3,874,000. Finally, Independence Bank of Kentucky lifted its stake in shares of Novo Nordisk A/S by 192.7% in the 3rd quarter. Independence Bank of Kentucky now owns 11,490 shares of the company's stock valued at $1,368,000 after purchasing an additional 7,565 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Buy" and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 1.5 %

Shares of NVO stock traded down $1.56 on Thursday, reaching $105.35. 4,466,006 shares of the company's stock traded hands, compared to its average volume of 4,440,815. The business's 50 day moving average price is $119.68 and its two-hundred day moving average price is $129.92. The company has a market capitalization of $472.76 billion, a P/E ratio of 34.47, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.